Robert Haddad
@drhaddadrobert
Division Chief, Head and Neck Oncology.
Dana Farber Cancer Institute.
McGraw Chair in Head and Neck Oncology
Professor of Medicine. Harvard Medical School
ID: 81911264
12-10-2009 19:45:37
200 Tweet
1,1K Followers
212 Following
Out today Biomarkers predictive of response to pembrolizumab in head and neck cancer onlinelibrary.wiley.com/doi/10.1002/ca… we assess combined biomarker analysis from K012 and 055 Ravi Uppaluri, MDPhD Nabil Saba, MD Sana Karam, MD, PhD Ezra Cohen
Pembrolizumab versus Cetuximab concurrent with radiotherapy in patient... sciencedirect.com/science/articl… No difference in outcomes.We still need to define SOC for cis ineligible pts . what is yours ? Nabil Saba, MD David Sher Robert Ferris, MD, PhD Sean McBride
Key question for trials is whether folks are comfortable randomizing to RT alone. The vote by Robert Haddad suggests only a quarter of us are willing but hopefully@more in the context of a trial for a cleaner answer
Our paper on CT performance with ENE shows poor reproducibility among expert head/neck neuroradiologists and poor predictive value for histologic ENE rdcu.be/c42sc. Benjamin Kann, MD Sue Yom Dana-Farber News Brigham and Women’s Radiology Education Brigham and Women's Hospital Dr (Prof). Vijay Patil
Finally out, our analysis from CONDOR/HAWK/EAGLE Tumor Mutational Burden as a Predictor of Survival With D+T in Recurrent Head and Neck Squamous Cell Carcinoma , also reporting on bTMB Robert Ferris, MD, PhD AstraZenecaUS Ezra Cohen AACR Ravi Uppaluri, MDPhD aacrjournals.org/clincancerres/…
TRIO Panel - Immunotherapy in H&N Cancer: What We Know, What We Think We Know and What We Really Don't. Join us tomorrow in Boston with the great Sana Karam, MD, PhD Lực Morris and Maie St. John COSM Triological Society . l.core-apps.com/cosm2023/event…
1/ Results from #COSMIC-313 are out NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by Charles Swanton Andres Cervantes #ESMO22 Thread 🧵==> nejm.org/doi/full/10.10…
First targeted therapy found safe and shows anti-tumor activity in patients with rare head and neck cancer. Dana-Farber's Robert Haddad, MD (Robert Haddad) details the findings that were presented at #ESMO23.
Out today--DC dysfunction in HNSCC antiPD1 resistance w/ a mechanistic role for CCL5 in enhancing DC function/ T cell priming. Congrats to Shin/Michi! Brigham and Women’s Department of Surgery Dana-Farber News Robert Haddad Glenn J. Hanna, M.D. Jonathan Schoenfeld tinyurl.com/686af9e9
I’m teaming up with Robert Haddad to play pickeball against Rob Gronkowski and raise funds for cancer research for Dana-Farber ! Help us beat the Gronk (and Cancer!) charity.pledgeit.org/f/ozX6IMVf7v
We are getting ready Rob Gronkowski and Julian Edelman !!! We hope you are practicing too ! Let us cure Cancer together ! #pickelball Dana-Farber Dana-Farber Lank Center for Genitourinary Oncology Robert Haddad The Jimmy Fund G O L D I E. New England Patriots Dana-Farber News charity.pledgeit.org/f/ozX6IMVf7v
Thank you Rob Gronkowski & Julian Edelman for a wonderful #pickleball game to benefit Dana-Farber The Jimmy Fund —we are in this together to beat Cancer ! Dana-Farber Robert Haddad Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber News Pan-Mass Challenge G O L D I E.
Did you know Robert Haddad and Toni Choueiri, MD had a competitive streak? - Dana-Farber Rob Gronkowski #Cancer #CancerResearch #DanaFarberCancerInstitute #YouthFoundation #Clinic #NationalCancerInstitute #OncoDaily #Oncology oncodaily.com/49490.html
